Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M245,619Revenue $M53,634Net Margin (%)18.5Z-Score4.3
Enterprise Value $M252,404EPS $4.1Operating Margin %21.4F-Score6
P/E(ttm))25.7Cash Flow Per Share $0Pre-tax Margin (%)23.6Higher ROA y-yY
Price/Book3.410-y EBITDA Growth Rate %-1.5Quick Ratio1.2Cash flow > EarningsY
Price/Sales4.85-y EBITDA Growth Rate %-0.9Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %14.6ROA % (ttm)8.1Higher Current Ratio y-yY
Dividend Yield %2.6Insider Buy (3m)0ROE % (ttm)14.3Less Shares Outstanding y-yY
Payout Ratio %63.0Shares Outstanding M2,399ROI % (ttm)0Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSLee Ainslie 2014-12-31 Add0.36%$85.02 - $96.65
($92.56)
$ 10311%Add 90.55%519,369
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 10311%Sold Out0
NVSJohn Hussman 2014-12-31 Reduce-0.4%$85.02 - $96.65
($92.49)
$ 10311%Reduce -23.36%164,000
NVSLee Ainslie 2014-09-30 Buy 0.38%$85.25 - $94.8
($90.27)
$ 10314%New holding, 272570 sh.272,570
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 10314%New holding, 7772 sh.7,772
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 10314%Reduce -98.51%9,646
NVSPRIMECAP Management 2014-09-30 Reduce-0.16%$85.25 - $94.8
($90.27)
$ 10314%Reduce -6.74%22,239,448
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 10317%Add 10.04%51,102,219
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 10317%Reduce -71.8%649,519
NVSLee Ainslie 2014-06-30 Sold Out -0.42%$82.51 - $90.98
($87.73)
$ 10317%Sold Out0
NVSLee Ainslie 2014-03-31 Add0.1%$78.2 - $83.82
($81.23)
$ 10327%Add 31.52%351,580
NVSPRIMECAP Management 2014-03-31 Reduce-0.26%$78.2 - $83.82
($81.23)
$ 10327%Reduce -10.13%24,014,586
NVSLee Ainslie 2013-12-31 Reduce-0.56%$72.96 - $80.39
($77.55)
$ 10333%Reduce -66.76%267,321
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 10340%Sold Out0
NVSLee Ainslie 2013-06-30 Add0.2%$68.42 - $75.5
($72.61)
$ 10342%Add 39.5%741,689
NVSJohn Hussman 2013-06-30 Reduce-0.52%$68.42 - $75.5
($72.61)
$ 10342%Reduce -47.49%218,900
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 10342%Sold Out0
NVSLee Ainslie 2013-03-31 Buy 0.49%$63.3 - $71.32
($67.87)
$ 10352%New holding, 531689 sh.531,689
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 10352%Reduce -85.39%726,200
NVSIrving Kahn 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 10352%Reduce -21.03%33,456
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
NVS Lee Ainslie 2014-12-31519,3690.020.75+90.55%
NVS Irving Kahn 2014-12-3130,96800.49+1.98%
NVS HOTCHKIS & WILEY 2014-12-319,66500+0.2%
NVS Jean-Marie Eveillard 2014-12-3112,84800
NVS Ken Fisher 2014-12-316,007,3650.251.2-0.13%
NVS PRIMECAP Management 2014-12-3122,168,6780.922.1-0.32%
NVS Dodge & Cox 2014-12-3150,324,6452.14.3-1.14%
NVS Mario Gabelli 2014-12-319,59000-5.89%
NVS Tweedy Browne 2014-12-31266,0370.010.63-6.32%
NVS John Hussman 2014-12-31164,0000.011.5-23.36%
NVS Ruane Cunniff 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15584.27view

Press Releases about NVS :

    Quarterly/Annual Reports about NVS:

      News about NVS:

      Articles On GuruFocus.com
      Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
      Can These Three BioTech Companies Make It Big? Feb 20 2015 
      Pfizer Takes A Giant Leap In Treatment of Cancer Feb 12 2015 
      The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
      Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
      Causeway International Value Fund 3Q 2014 Letter to Shareholders Dec 22 2014 
      Dividend Aristocrats In Focus Part 52 of 54: Johnson & Johnson Dec 03 2014 
      Kahn Brothers' Third Quarter Numbers Nov 07 2014 
      Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
      Zoetis Will Benefit from Industry Trends Oct 07 2014 


      More From Other Websites
      Pharmacyclics mulls sale; J&J, Novartis interested - Bloomberg Feb 25 2015
      GSK to be No. 1 vaccine producer when it completes $25B asset swap with Novartis next week Feb 25 2015
      GSK set to complete $20 billion Novartis asset swap next week Feb 25 2015
      GSK set to complete 13 billion pounds Novartis asset swap next week Feb 25 2015
      GSK set to complete $20 bln Novartis asset swap next week Feb 25 2015
      GSK set to complete $20 bln Novartis asset swap next week Feb 25 2015
      Update on three-part transaction with Novartis Feb 25 2015
      Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog Feb 24 2015
      Brain-Altering Devices May Supplant Drugs -- And Pharma Is OK With That Feb 24 2015
      In The Book Of Life, A Second Map Is Established Feb 24 2015
      United Therapeutics Blood Pressure Drug Lifts Q4 Feb 24 2015
      Hot Income Stocks: Who's Growing Dividends The Fastest? Feb 23 2015
      FDA approves Novartis drug for bone marrow cancer Feb 23 2015
      FDA approves Novartis drug for bone marrow cancer Feb 23 2015
      Novartis AG wins approval to buy GSK cancer drugs, with conditions Feb 23 2015
      Australian regulator says will not oppose GSK, Novartis deals Feb 19 2015
      Australian regulator says will not oppose GSK, Novartis deals Feb 19 2015
      Momenta (MNTA) Posts Wider-than-Expected Loss in Q4 - Analyst Blog Feb 18 2015
      Can Veeva Systems' Software Keep Luring Big Pharma? Feb 17 2015
      Novartis' (NVS) Cardiovascular Drug Granted Priority Review - Analyst Blog Feb 16 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK